CASE REPORT article
Front. Gastroenterol.
Sec. Therapy in Gastroenterology
Volume 4 - 2025 | doi: 10.3389/fgstr.2025.1626455
This article is part of the Research TopicAdvances in Inflammatory Bowel Disease: Treatment, Targets and TherapyView all 6 articles
Case report: Rapid resolution of fever after initiation of third-line rescue treatment with upadacitinib for acute severe ulcerative colitis in two young men
Provisionally accepted
- Heidelberg University Hospital, Heidelberg, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The case report presents a novel therapeutic option in acute severe ulcerative colitis which remains a life-threatening and challenging scenario in clinical gastroenterology. It emphasizes the potential of upadacitinib, a JAK1 selective JAK inhibitor, as a medical rescue option in this situation and will be of great interest to the readers of the Research Topic which deals with Advances in Therapy in Inflammatory Bowel Diseases. As there is a lack of therapeutic options in acute severe ulcerative colitis, upadacitinib appears to be a very valuable therapeutic option. The original aspects of our case report are 1. that both reported patients suffered from fever prior to start of upadacitinib treatment, 2. that upadacitinib was used after steroid and infliximab failure, and 3. that we provide a one-year follow-up for one of the patients.
Keywords: Acute severe ulcerative colitis (ASUC), Upadacitinib, Fever, Rescue treatment, case report
Received: 10 May 2025; Accepted: 25 Jul 2025.
Copyright: © 2025 Pinzaru, Kreysing, Lesmeister, Schwandner, Michl and Gauss. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Annika Gauss, Heidelberg University Hospital, Heidelberg, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.